Skip to content
Search

Latest Stories

Recall report of blood pressure drugs 'misleading'

The Royal Pharmaceutical Society (RPS) has confirmed that the recall of blood pressure drugs amlodipine and olmesartan by the Food and Drug Administration is only for the US market and will not have any impact in the UK.

MHRA also clarified that the manufacturer of these drugs, Macleod Pharmaceuticals, does not supply amlodipine medicines in the UK.

It was published online in both the Daily Record and Daily Express on the morning of Monday, March 21, that the drugs had been recalled in the US by the FDA due to deviations from standard manufacturing protocols by the manufacturer.


RPS intervened to ensure the articles were edited to make clear that this is not an issue in the UK after confirmation from the MHRA. Amlodipine tablets from Macleod Pharmaceuticals aren't available for wholesale distribution in the UK.

An MHRA statement said: “The MHRA has confirmed that the recall of combined Amlodipine/Olmesartan Medoxomil tablets 10 mg/20 mg, batch number BAD62101A (expiry Feb 24), is for the US market only – while Macleods Pharma does supply other medicines to the UK, this particular product is not available here.”

"Patients seeking advice can be reassured that the amlodipine and olmesartan provided by the NHS is not affected by the recall in the USA," assures RPS.

More For You

Shadow Health Minister raised concerns about the impact of NICs hike on healthcare

Shadow Health Minister Dr Caroline Johnson MP speaking during a House of Commons debate on Wednesday

MPs slam government over national insurance hike, warn of impact on pharmacies

Shadow Health Minister Dr Caroline Johnson MP has criticised the Labour government for increasing employer National Insurance Contributions (NICs), without properly considering its effects on the wider healthcare system.

Speaking during a House of Commons debate on Wednesday, she warned of the significant strain the rise in national insurance and taxes will place on pharmacies and the wider healthcare sector.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Asda pharmacy launches UK’s first adult earache service

Asda makes ear health more accessible for everyone

gettyimages

Asda pharmacy launches £25 adult earache service

British supermarket chain Asda has launched the “UK’s first” adult earache service, aiming to reduce the burden on NHS services by eliminating the need for a GP appointment.

Priced at £25, the service allows patients aged 18 and over to book same-day appointments with qualified Asda pharmacists at any of its 226 pharmacies in England.

Keep ReadingShow less
Dr Penelope Dash new chair of NHS England

Dr Penny Dash is currently the chair of the NHS North West London Integrated Care Board

parliamentlive

Dr Penelope Dash appointed as new chair of NHS England

Dr Penny Dash has been appointed as the next chair of NHS England following an open public appointment process.

She will succeed Richard Meddings, who is set to step down next month, and her four-year term begins on April 1, 2025.

Keep ReadingShow less